Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
77 hedge funds and large institutions have $956M invested in Kronos Bio in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 11 closing their positions.
183% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 12
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
8% more funds holding
Funds holding: 71 → 77 (+6)
6.85% more ownership
Funds ownership: 64.27% → 71.11% (+6.8%)
9% less capital invested
Capital invested by funds: $1.05B → $956M (-$93.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38M |
| 2 |
BlackRock
New York
|
+$30M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$29.5M |
| 4 |
CIA
Choate Investment Advisors
Boston,
Massachusetts
|
+$9.03M |
| 5 |
State Street
Boston,
Massachusetts
|
+$8.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$18.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.38M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.91M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$5.7M |
KRON Hedge Fund Activity: Q2 2021 in Review
77 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q2 2021, worth a combined $956M — down 8.9% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KRON positions and 11 closed out — a net gain of 6 holders — while 34 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $38M. The largest seller was Capital Research Global Investors, cutting an estimated $18.9M.
- 77 institutional investors held Kronos Bio (KRON) as of Q2 2021, up from 71 in Q1 2021.
- Funds reported $956M of Kronos Bio stock for Q2 2021, down 8.9% quarter-over-quarter.
- 17 funds opened new Kronos Bio positions in Q2 2021 and 11 closed out, a net change of +6 holders.
- The largest Kronos Bio buyer in Q2 2021 was Vanguard Group, an estimated $38M added.
- The largest Kronos Bio seller in Q2 2021 was Capital Research Global Investors, an estimated $18.9M sold.
Based on aggregated 13F filings for Q2 2021.